Table 2.
Treatment outcome of HPOA patients with EGFR sensitive mutation
| No | Gender | Age | EGFR | Stage | TKIs | PFS (m) | OS (m) |
|---|---|---|---|---|---|---|---|
| 1 | Female | 77 | L858R | Ib | Gefitinib | 2.5 | 36.0* |
| 2 | Female | 53 | Exon 19 deletion | IV | Gefitinib | 5.9 | 52.6 |
| 3 | Male | 68 | Exon 19 deletion | IIIb | Erlotinib | 8.2 | 29.0 |
Note:
*
From cancer recurrence to patient deceased.
Abbreviations: (m), months; No, number; EGFR, epidermal growth factor receptor; HPOA, hypertrophic pulmonary osteoarthropathy; TKIs, tyrosine kinase inhibitors; PFS, progression-free survival; OS, overall survival.